Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Bolt Biotherapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- −5 vs. Q1 2025
- Shares held
- 887.5K
- −28.8K (−3.1%) vs. Q1 2025Converted for a 1-for-20 split
- Total value
- $5.10M
- −$2.23M (−30.5%) vs. Q1 2025
- New holders
- 2
- 3 more added
- Sold out
- 7
- 9 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 176,064 | $986.0K | 0.10% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Tang Capital Management LLC | 166,879 | $962.9K | 0.05% | −23,760−12.5% | ReducedConverted for a 1-for-20 split |
| Sofinnova Investments, Inc. | 137,721 | $794.6K | 0.05% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Pivotal bioVenture Partners Investment Advisor LLC | 94,573 | $545.7K | 0.34% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Vanguard Group Inc | 58,484 | $341.0K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Nan Fung Group Holdings Ltd | 58,347 | $336.7K | 0.53% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Samsara BioCapital, LLC | 52,456 | $302.7K | 0.06% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Board of Trustees of The Leland Stanford Junior University | 35,978 | $207.6K | 0.02% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Pfizer Inc | 31,305 | $180.6K | 0.03% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Geode Capital Management, LLC | 18,533 | $108.1K | 0.00% | −223−1.2% | ReducedConverted for a 1-for-20 split |
| Renaissance Technologies LLC | 18,325 | $105.7K | 0.00% | +2,618+16.7% | AddedConverted for a 1-for-20 split |
| Squarepoint Ops LLC | 12,388 | $72.2K | 0.00% | +8,193+195.3% | AddedConverted for a 1-for-20 split |
| ADAR1 Capital Management, LLC | 10,823 | $62.4K | 0.01% | −1,425−11.6% | ReducedConverted for a 1-for-20 split |
| BlackRock, Inc. | 10,550 | $60.9K | 0.00% | −2,882−21.5% | ReducedConverted for a 1-for-20 split |
| Morgan Stanley | 3,579 | $20.7K | 0.00% | +2,998+516.3% | AddedConverted for a 1-for-20 split |
| GWM Advisors LLC | 483 | $2.79K | 0.00% | +483 | New |
| Tower Research Capital LLC (TRC) | 395 | $2.28K | 0.00% | −39−9.1% | ReducedConverted for a 1-for-20 split |
| Bank of America Corp | 282 | $1.63K | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| UBS Group AG | 183 | $1.06K | 0.00% | −5,392−96.7% | ReducedConverted for a 1-for-20 split |
| FMR LLC | 121 | $705 | 0.00% | −284−70.1% | ReducedConverted for a 1-for-20 split |
| JPMorgan Chase & Co | 43 | $251 | 0.00% | −2−5.1% | ReducedConverted for a 1-for-20 split |
| SBI Securities Co., Ltd. | 10 | $58 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Barclays PLC | 6 | $35 | 0.00% | −1−13.7% | ReducedConverted for a 1-for-20 split |
| Salem Investment Counselors Inc | 2 | $12 | 0.00% | 00.0% | UnchangedConverted for a 1-for-20 split |
| Danske Bank A/S | 1 | $6 | 0.00% | +1 | New |
| State Street Corp | 0 | $0 | 0.00% | −2,372−100.0% | Sold outConverted for a 1-for-20 split |
| Northern Trust Corp | 0 | $0 | 0.00% | −2,045−100.0% | Sold outConverted for a 1-for-20 split |
| Mariner, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold outConverted for a 1-for-20 split |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −1,087−100.0% | Sold outConverted for a 1-for-20 split |
| StoneX Group Inc. | 0 | $0 | 0.00% | −777−100.0% | Sold outConverted for a 1-for-20 split |
| XTX Topco Ltd | 0 | $0 | 0.00% | −770−100.0% | Sold outConverted for a 1-for-20 split |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −0−100.0% | Sold outConverted for a 1-for-20 split |